Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Hamm – page 39

1 110 clinical trials in Hamm, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hamm at a glance
1 110
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 110 trials in Hamm

Open in trial search

Neuroendocrine carcinoma

Not yet recruiting

Phase II Study of BI 764532 Added to Platinum Chemotherapy in Adults with Advanced Large‑Cell Neuroendocrine Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Technische Universitat Dresden

Irritable bowel syndrome

Not yet recruiting

Efficacy and Safety of Amara‑Tropfen Dilution vs Placebo in Patients with Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Artemisia absinthium, herba REC., ethanol. EXTR. 1:2,3
  • Sponsor:Weleda AG

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Gildeuretinol acetate
  • Sponsor:Alkeus Pharmaceuticals Inc.

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Cartilage injury

Not yet recruiting

Non‑inferiority study of autologous minced cartilage and autologous cultured chondrocytes in adults with large full‑thickness knee cartilage defects

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Chondroitin sulfate
  • Sponsor:Medical Center - University Of Freiburg

Huntington's disease

Not yet recruiting

Phase 2/3 Randomized Study of SKY-0515 for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SKY-0515
  • Sponsor:Skyhawk Therapeutics Inc.

Lichen sclerosus

Not yet recruiting

A Phase 3 Study of Delgocitinib Cream to Evaluate Efficacy and Safety in Adult Women with Lichen Sclerosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Delgocitinib
  • Sponsor:LEO PHARMA A/S

Phase II study of autologous enriched T‑cell therapy expressing CD19 and CD22 CARs in Philadelphia‑negative B‑precursor ALL patients with measurable residual disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Goethe University Frankfurt

Acute lymphocytic leukaemia

Not yet recruiting

Study of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Endocarditis bacterial

Not yet recruiting

Dalbavancin versus standard drug combination for treatment of infective endocarditis caused by Gram‑positive cocci in adult patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Atrial fibrillation

Not yet recruiting

Colchicine after Electrocardioversion to Prevent Recurrence of Atrial Fibrillation in Adult Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Universitaetsspital Basel

Relapsing multiple sclerosis+1

Not yet recruiting

Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous Ocrelizumab in Children and Adolescents with Relapsing‑Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Hamm

What the registry says about research in the country

01 Hematologic Oncology

Innovative clinical trials focusing on blood cancers and related disorders, including studies of new treatment approaches for chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.

  • Novel drug combinations for CLL/SLL treatment
  • Multiple myeloma therapies
  • Advanced leukemia treatments

Research emphasizes personalized medicine approaches and targeted therapies to improve patient outcomes.

02 Solid Tumors

Comprehensive research into various types of solid tumors, with particular focus on breast cancer, lung cancer, and gastrointestinal cancers.

  • Triple-negative breast cancer treatments
  • Non-small cell lung cancer therapies
  • Colon cancer interventions

Studies explore both neoadjuvant and adjuvant treatment approaches.

03 Dermatological Conditions

Clinical investigations of various skin conditions, including actinic keratosis, rosacea, and atopic dermatitis.

  • Novel topical treatments
  • Comparative efficacy studies
  • Inflammatory skin conditions

Research focuses on both innovative and established therapeutic approaches for skin disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.